- Home
- NIVF vs WINT Comparison
NIVF vs WINT Comparison
Compare NIVF & WINT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NIVF
- WINT
- Stock Information
- Founded
- NIVF 2011
- WINT 1992
- Country
- NIVF Thailand
- WINT United States
- Employees
- NIVF N/A
- WINT N/A
- Industry
- NIVF
- WINT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NIVF
- WINT Health Care
- Exchange
- NIVF NYSE
- WINT Nasdaq
- Market Cap
- NIVF 2.1M
- WINT 2.2M
- IPO Year
- NIVF N/A
- WINT 1995
- Fundamental
- Price
- NIVF $0.62
- WINT $0.73
- Analyst Decision
- NIVF
- WINT Hold
- Analyst Count
- NIVF 0
- WINT 1
- Target Price
- NIVF N/A
- WINT $350.00
- AVG Volume (30 Days)
- NIVF 3.8M
- WINT 9.9M
- Earning Date
- NIVF 01-01-0001
- WINT 08-18-2025
- Dividend Yield
- NIVF N/A
- WINT N/A
- EPS Growth
- NIVF N/A
- WINT N/A
- EPS
- NIVF N/A
- WINT N/A
- Revenue
- NIVF $5,433,375.00
- WINT N/A
- Revenue This Year
- NIVF N/A
- WINT N/A
- Revenue Next Year
- NIVF N/A
- WINT N/A
- P/E Ratio
- NIVF N/A
- WINT N/A
- Revenue Growth
- NIVF 5.79
- WINT N/A
- 52 Week Low
- NIVF $0.61
- WINT $0.36
- 52 Week High
- NIVF $656.00
- WINT $737.44
- Technical
- Relative Strength Index (RSI)
- NIVF 27.45
- WINT 52.59
- Support Level
- NIVF $0.61
- WINT $0.63
- Resistance Level
- NIVF $1.24
- WINT $1.02
- Average True Range (ATR)
- NIVF 0.12
- WINT 0.12
- MACD
- NIVF 0.03
- WINT 0.03
- Stochastic Oscillator
- NIVF 2.36
- WINT 56.06
About NIVF NEWGENIVF GROUP LIMITED
NewGenIvf Group Ltd is a company engaged in providing assisted reproductive services in Asia Pacific with a focus on providing fertility treatments to fulfil the dreams of building families, NewGenIvf mainly offers two services, namely first which is a in-vitro fertilization (IVF) treatment service, comprising traditional IVF and egg donation; and surrogacy and ancillary caring services.
About WINT Windtree Therapeutics Inc.
Windtree Therapeutics Inc is a biotechnology company focused on advancing early and late-stage therapies for critical conditions and diseases. Its portfolio of product candidates includes istaroxime, a Phase 2 candidate with sarco endoplasmic reticulum Ca2+ -ATPase 2a, or SERCA2a, activating properties for acute heart failure and associated cardiogenic shock, preclinical SERCA2a activators for heart failure, rostafuroxin for the treatment of hypertension in patients with a specific genetic profile, and a preclinical atypical protein kinase C iota, or aPKCi, inhibitor, being developed for potential application in rare and broad oncology indications. It operates in one operating segment, which is the research and development of products focused on cardiovascular disease.